Search results: (10000)
News Another Piece of the Puzzle for More Accurate Dosing of Clotting Factors in von Willebrand Disease
A study published last year in the Journal of Thrombosis and Haemostasis presents the results of Dutch hematologists who created a pharmacokinetic model to refine the dosing of clotting factors during surgery in patients with von Willebrand disease (vWD).
News Safety and Effectiveness of Lurasidone in Adolescents with Schizophrenia
An open-label extension of a placebo-controlled study involving 271 patients aged 13–17 years with schizophrenia showed minimal impact on body weight, lipid levels, prolactin, and blood glucose during 2 years of treatment while maintaining and deepening the alleviation of schizophrenia symptoms.
News Can sartans improve clinical outcomes in hypertensive patients with COVID-19?
Dysfunction of the renin-angiotensin system (RAS) has been detected in patients with COVID-19. This finding led to the hypothesis that RAS inhibitors (RASi) could help these patients. To verify this, a retrospective study was conducted, the results of which we briefly summarize.
News Role and Possibilities of Telemedicine in the Management of Hemophilia Care
A team of Irish experts recently evaluated the current possibilities of telemedicine in the care of individuals with hemophilia – not only from the perspective of care provided by specialized comprehensive centers but also considering physiotherapy and dental care.
News Does idarucizumab reverse the anticoagulant effect of dabigatran regardless of renal function?
The drugs idarucizumab and dabigatran are excreted by the kidneys. The RE-VERSE AD study investigated whether the renal function of patients affects the extent of the reversing effect of idarucizumab on the effect of dabigatran.
News New Treatment Option for Metastatic Pancreatic Cancer – Pegylated Liposomal Irinotecan
The 2019 review article is dedicated to the use of nanoliposomal irinotecan, its toxicity, and its potential use in the treatment sequence of metastatic pancreatic ductal adenocarcinoma.
News Sport as an Important Part of the Life of Hemophiliacs
People with congenital bleeding disorders have very diverse approaches to sports and exercise. The possibility of preventing bleeding by administering safe and effective medications for these patients clearly supports engagement in an active physical life.
News Can Co-administration of Dabigatran with Antiretroviral Drugs Be Effective and Safe?
In 2019, the first results regarding the concurrent use of antiretroviral drugs and oral anticoagulants were published. This involved 14 patients with atrial fibrillation and HIV infection, in whom the concurrent administration of dabigatran with antiretroviral drugs was not associated with the occurrence of thromboembolic events or bleeding during follow-up lasting up to 40 months.
News Diabetic Nephropathy and COVID-19: Fatal Connection?
People with diabetes and diabetic kidney disease exhibit higher mortality and risk of severe illness in connection with COVID-19. The worse prognosis of these patients likely has multiple reasons; in the following overview, we will focus mainly on the cellular receptor of the SARS-CoV-2 virus – angiotensin-converting enzyme 2 (ACE2).
News Efficacy of Panitumumab in the Treatment of Refractory mCRC
A meta-analysis of 7 clinical trials showed that panitumumab therapy demonstrates a higher overall response rate compared to controls in patients with refractory metastatic colorectal cancer (mCRC).
News Current Results of Brigatinib in the Treatment of Lung Cancer
The results of the primary analysis showed a significant extension of PFS in patients with non-small cell lung cancer (NSCLC) treated with brigatinib compared to crizotinib. The recently published secondary analysis confirms these results.
News Impact of Lurasidone on Metabolic Functions Compared to Other Antipsychotics – Results of a Large Meta-Analysis
Antipsychotic therapy is associated with varying degrees of metabolic abnormalities in parameters of weight, lipid metabolism, and glucose metabolism. The presence of metabolic syndrome or isolated disorders of glucose and lipid metabolism further increases the risk of morbidity and mortality in patients with schizophrenia compared to the general population. Lurasidone is an antipsychotic indicated for the acute and maintenance treatment of schizophrenia. The advantage of this drug is its low risk of metabolic side effects, which has been confirmed in a recent large meta-analysis of clinical studies.
News Impact of Physiotherapy and Sports Activities on the Results of Movement Tests in Children with Hemophilia
At the 9th Hemophilia Academy, held online from October 5-7 in Budapest, a lecture by Mgr. Marie Katzerová from University Hospital Brno titled “Physiotherapy, Sports, and Hemophilia” aimed to elucidate the impact of physical activity on the results of movement tests in children with hemophilia.
News Clinical Experiences with Reversing Dabigatran with Idarucizumab
Idarucizumab is an effective specific antidote to dabigatran, which very quickly negates its coagulative effects in cases of severe bleeding conditions or emergency surgical procedures. A Danish retrospective study examined clinical experiences with the use of idarucizumab for blocking dabigatran and related clinical outcomes.
News Real Impact of Lockdown on Asthma Treatment – EAACI Survey Results
Restrictions associated with the COVID-19 pandemic have had a significant impact on the treatment of chronic diseases such as asthma. A study published in the journal Allergy focused on evaluating treatment approaches for adult and pediatric patients with asthma during the coronavirus pandemic lockdowns.
News Efficacy of Brigatinib in Patients with Metastatic NSCLC − Real-World Clinical Data
The journal Lung Cancer published the results of a retrospective analysis of the efficacy of brigatinib in patients with ALK-positive metastatic non-small cell lung cancer (NSCLC) who participated in a European early access treatment program.
News Expanded Hemodialysis and Its Impact on Reducing Hospitalization Rates and Medication Usage
The number of patients with end-stage kidney disease is increasing. New approaches and technological advancements in recent decades have contributed to improving hemodialysis treatment. Does the use of so-called expanded hemodialysis lead to better outcomes?
News Efficacy and Safety of Axitinib in Higher Lines of Renal Carcinoma Treatment in Real Practice
Greek authors published a retrospective study from a single institution and demonstrated that axitinib is a safe and effective treatment option for metastatic renal carcinoma even in ≥ 3rd line treatment.
News Does dabigatran use in women with acute venous thromboembolism reduce the risk of uterine bleeding compared to warfarin?
The use of new oral anticoagulants (NOACs) in patients with deep vein thrombosis is associated with a more favorable safety profile compared to warfarin. However, direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) pose a higher risk of abnormal uterine bleeding. The study presented below compared the risk of this bleeding when using dabigatran (a direct thrombin inhibitor) and warfarin.
News Reduction of Risk of Hospitalizations for Heart Failure in Type 2 Diabetics
The EMPA-REG OUTCOME study already in 2015 highlighted one of the benefits of the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin, which is the reduction of the risk of hospitalization for heart failure in patients with type 2 diabetes mellitus (T2DM) with high cardiovascular (CV) risk. Compared to placebo, empagliflozin reduced this risk by a relative 35%.
News Efficacy and Safety of Enoxaparin as Bridging Anticoagulant Therapy After Ventricular Assist Device Implantation
The implantation of a ventricular assist device has become an increasingly common method in the treatment of end-stage heart failure in recent years. The implantation of the device necessitates anticoagulant therapy. In the long term, warfarin is most often used according to guidelines, but there are no clear recommendations for early postoperative anticoagulant therapy. The aim of a clinical study published last year was to evaluate the efficacy and safety of enoxaparin as bridging anticoagulant therapy after device implantation within a 3-month postoperative period.
News Biosimilar MB02 as an Alternative to Bevacizumab in Lung Cancer Treatment
The STELLA clinical trial aimed to evaluate the efficacy, safety, and immunogenicity of MB02, a biosimilar to bevacizumab, in patients with advanced non-small cell lung cancer.
News Efficacy and Safety of Gefitinib in Combination with Chemotherapy vs. Chemotherapy Alone in the Treatment of Advanced NSCLC
Non-small cell lung cancer (NSCLC) remains a disease with high mortality. The meta-analysis presented below compared the efficacy and safety of gefitinib in combination with chemotherapy versus chemotherapy alone in the treatment of advanced NSCLC.
News Treatment of Metastatic Colorectal Cancer During the COVID-19 Pandemic
In the conditions of the coronavirus pandemic, it is difficult to maintain good accessibility to ongoing comprehensive oncological care, and thus the quality of life of patients. An international team of researchers focused their survey among oncologists on how the pandemic affects the goals of 3rd line therapy in patients with metastatic colorectal cancer (mCRC) in real clinical practice. The survey results were presented at this year's virtual congress on the treatment of gastrointestinal tumors of the European Society for Clinical Oncology (ESMO).
News Brigatinib in the Therapy of ALK-Positive NSCLC – First Results of the J-ALTA Study
Brigatinib is an anaplastic lymphoma kinase (ALK) inhibitor with broad and potent activity against ALK gene mutations causing resistance to ALK inhibitor therapy (ALKi). In patients refractory to crizotinib therapy, brigatinib administration in phase III clinical trials led to high systemic and intracranial therapeutic responses and concurrently improved median progression-free survival (PFS). The primary analysis objective of the phase II J-ALTA clinical study, presented at this year's American Society of Clinical Oncology (ASCO) congress, was to assess the efficacy and safety of therapy in patients with ALK-positive NSCLC naïve to previous ALKi therapy.